NeuroOne Medical Technologies starts limited commercial launch of OneRF Ablation System

NEUROONE MEDICAL TECHNOLOGIES Corp

OneRF System is FDA 510(k)-cleared for creating RF lesions in nervous tissue for functional neurosurgery.
CEO Dave Rosa expects shipping to begin this week with first cases scheduled in April 2024.
First therapeutic device for NeuroOne; third FDA 510(k)-cleared device alongside Evo electrode lines.
Company estimates the brain ablation market at least $100M worldwide with significant growth potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.